A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (NCT02960022)
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Who can join: Review the eligibility criteria below.
Location: Site US10052 — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (234 Sites)
Showing the first 25 of 234 sites.
- Site US10052 — Anchorage, Alaska
- Site US10011 — Tucson, Arizona
- Site US10040 — Los Angeles, California
- Site US10009 — Los Angeles, California
- Site US10008 — San Bernardino, California
- Site US10042 — San Diego, California
- Site US10028 — Stanford, California
- Site US10001 — Aurora, Colorado
- Site US10017 — Denver, Colorado
- Site US10050 — Washington D.C., District of Columbia
- Site US10049 — Daytona Beach, Florida
- Site US10002 — Chicago, Illinois
- Springfield Clinic, LLP — Springfield, Illinois
- Site US10007 — Jeffersonville, Indiana
- University of Kansas Medical Center — Kansas City, Kansas
- Site US10066 — Lenexa, Kansas
- Site US10029 — Towson, Maryland
- Site US10032 — St Louis, Missouri
- Nebraska Medical Hospital — Omaha, Nebraska
- Site US10023 — Omaha, Nebraska
- Site US10004 — Hackensack, New Jersey
- Site US10024 — Garden City, New York
- Site US10055 — New York, New York
- Site US10059 — New York, New York
- Hudson Valley Urology, PC — Poughkeepsie, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.